Sugemalimab
Modify Date: 2025-08-31 20:20:10
Sugemalimab structure
|
Common Name | Sugemalimab | ||
|---|---|---|---|---|
| CAS Number | 2256084-03-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SugemalimabSugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1]. |
| Name | Sugemalimab |
|---|
| Description | Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599. |
| No Any Chemical & Physical Properties |